Thus, a B7-H3 × CD28 bispecific antibody, XmAb808, synergizes with anti-PD-1 and CD3-engaging therapies, minimizing systemic activation while increasing T-cell activation and tumor infiltration [233]. The gene discussed is CD276; the disease is neoplasm.